Some exciting developments in value-based insurance design (VBID) have been the introduction of clinically nuanced cost sharing in Medicare Advantage programs, as well as the alignment of demand-side and supply-side payment reform initiatives, according to A. Mark Fendrick, MD, director of the Center for Value-Based Insurance Design at the University of Michigan.
Some exciting developments in value-based insurance design (VBID) have been the introduction of clinically nuanced cost sharing in Medicare Advantage programs, as well as the alignment of demand-side and supply-side payment reform initiatives, according to A. Mark Fendrick, MD, director of the Center for Value-Based Insurance Design at the University of Michigan.
Transcript (slightly modified)
What will the value-based insurance landscape look like in 2020?
There’s lots of momentum for value-based insurance design, or VBID, coming from both public and private payers. In the public space, we’re very excited about the launch of the value-based insurance design Medicare Advantage demonstration project, launching in January 1, 2017, in 9 health plans in 3 states, looking at common chronic conditions.
To see clinically nuanced cost sharing in the Medicare program is extraordinarily exciting for us, given that it was a very long and tenuous adjuvacy discussion, and now that we’ve seen a big uptake from both CMS and health plans to bring about lower out-of-pocket spending to Medicare beneficiaries, to get them the visits, the diagnostic tests, the drugs, and the procedures they need to manage their chronic diseases, is going to be a great step forward.
And to see this VBID demand-side initiative tied to the very exciting supply-side payment reform initiatives that are taking place across the country, should finally allow us to see alignment of quality-based incentives for both providers and patients.
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Dr Michael Farwell on FDG PET/CT Imaging to Predict Immunotherapy Response in Advanced Melanoma
April 15th 2024Michael Farwell, MD, associate professor of radiology at the Hospital of the University of Pennsylvania, provides insights into a study on the benefits of using 18F-fluorodeoxyglucose (FDG) PET/CT imaging to detect metabolic tumor changes in skin cancer.
Read More